U.S. Markets closed

Antares Pharma, Inc. (ATRS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.51-0.04 (-1.57%)
At close: 4:00PM EDT

2.56 0.05 (1.99%)
After hours: 5:03PM EDT

People also watch
  • FDA Chief wants to speed up the process for generic approvals. Mentions EPI Pen...

    FDA chief says agency needs to play a role in constraining drug prices by easing path for generics
    New FDA Commissioner Scott Gottlieb, M.D. plans a multifaceted effort to put the brakes on drug price increases via his "Drug Competition Action Plan." In a session before a House appropriatio
  • It is interesting that on May 23rd, 2017 Teva received FDA approval for Naloxone, sublingual tablet. Naloxone is used for Opioid overdose and is known as Narcan. I believe this is of interest because Antares mentioned they were working on life saving drugs for things such as opioid overdose...
  • Pretty pathetic that the FDA and TEVA has not gotten a generic Epi across the finish line yet.
  • Posted by Larry Smith on Nov 16, 2016

    Eyal Desheh is the Chief Financial Officer of Teva. During the recent third quarter conference call, he answered a question from an analyst about the development status of the AB rated generic to EpiPen. He said: “In terms of EpiPen, we are working very closely with the FDA. I haven’t changed my view. My expectation for EpiPen is still early 2018. There is nothing to change my view on that. We are still moving forward in good collaboration with the FDA. We have the meeting with the FDA. We understand the way forward, what needs to be done. We think pretty well. But it hasn’t changed my best estimate on the EpiPen launch.”

    GO ATRS!!!

  • Barclay note Dec 2014...".Mylan's spring loaded delivery vs Teva's operator force could make approval difficult." Barclay has always been against Anteras
  • Consortium adds throughout retrace, Stockvadar-reports

    The story on Antares hasn't changed since Apple took over:
    they are rapidly moving to profitability and have a T- ROW
    to replenish the coffers... and Rescuject despite the fear-
    mongering for Epi-.

    But in addition to so many applications before the FDA,
    Antares is finally letting it be known that they have other
    projects in the works to continue to build long-term
    valuation. This, in our opinion, has mostly gone ignored
    except for a few savvy posts. Antares is apparently working
    on combination injections that Lokodaug has been wagging
    his tail about--good for him.

    As to why the stock retraced we see it as healthy for the
    long-term. WE've made our own sizeable purchases and
    are generally pleased to contemplate the long-term. TEVA
    knows how to bring a project to completion and WE remain
    confident that Epi news is coming any day.

    Irrespective WE hope to add another chunk to OUR
    portfolio should it again dip. If not, it's off for the ride
    which is going to be much much higher come 2018.

    It's interesting when your banker calls for advice, but
    apparently OUR savvy gains in Antares has drawn
    some attention. Finally, we're still a bit puzzled about
    what "M" is but are now wondering if Antares has plans
    to fast-forward one of its combination projects? Lokodaug
    might know as i-t eats the crumbs under Jack's table.

  • Fade forward to this time next year...50,000 QST scripts/month @ low 250$each to high $350= 12.5M$/month low to 17.5M$/month on high side...this equals a 10% capture of entire script market USA/month. Easy pleasy to do, IMO.

    So in one year, just one drug per month will eclipse the current TOTAL company monthly rev. run rate...elevator UP to the penthouse!

    Sure, we have to cross the bridge right before us. Oh yeah, what happens if Makena gets approved at the same time as QST? In the cartoon world that's called a BONGO-CONGO event.

    I'd love to see this little operation hit $200M/yr for '18...about a 400% increase over a "slow" '17. The green-hounds on the street will sniff this out sooner than later.
  • Short interest down a bit again.

    Settlement Date Short Interest Avg Daily Share Volume Days To Cover
    5/15/2017 2,225,067 1,297,201 1.715283
    4/28/2017 2,579,904 2,142,255 1.204294
    Antares Pharma, Inc. (ATRS) Short Interest
    Antares Pharma, Inc. (ATRS) Short Interest � Find short interest for Antares Pharma, Inc. and all the companies you research at NASDAQ.com
  • Russell Loading......we are pinned here till they are done or news happens
  • Let the games continue :) Cant wait to get these approvals so the day to day games in the 2's can stop :) Its only a matter of time, love to see the excuse FDA would have now not to allow EPI generic into market it would be VERY interesting. I really dont see how its possible at this point, but FDA loves money almost as much as mylan LOL :)
  • Waiting for the FDA
  • We had an unbelievable run back up to 3's, but right now its just dead money until we start getting approvals, partnerships, ect. Epi will be here soon FINALLY should be approved in here in June at the latest. I believe we will be getting another turn around in June with EPI, I think with the fear of that shelf that was brought out, manipulation is being used against that fear. FDA needs to just get it done already this horse has been beaten to death already, get the paperwork signed and file it already with approval of epi so we can move on to the next. Long & Strong
  • Why hasn't Joe Manchin and his obvious role in obstructionism been mentioned anywhere in this discussion?
    JOE MANCHIN IS THE REASON. His daughter runs a drug company in a competing space.
  • Nam, here is a link:

    They took it up several month before and then down, similar to current pattern.
    I'm looking for short interest to have a large jump after the addition, but also hopping for a QST deal that will drive it higher.

    Antares Pharma, Inc. ATRS Post # 34
    Antares Pharma, Inc. ATRS Stock Message Board: [b]Antares Pharma Added to Russell 3000 Index[/b]
  • May 25, 2017  
    Gottlieb seeks more robust generic competition


    Gottlieb used his time on Capitol Hill to announce that FDA is developing a “drug competition action plan.”

    GO ATRS!!!

    Gottlieb seeks more robust generic competition
    Gottlieb seeks more robust generic competition
  • To the moon baby, to the moon
  • Reason for the drop today. What the heck to these analysts know anyway.

    Barclays believes Mylan's base business appears on a more solid footing, on stabilizing generic pricing, performance potential of Meda, resolution of Agila warning letters and expectation that Epipen would stabilize.

    "We don't expect Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) to win AB-rating (ironically, the same questions on device interchangability that might block MYL's Advair ANDA will make approval of TEVA's product difficult," the firm said.
  • https://finance.yahoo.com/news/edited-transcript-atrs-earnings-conference-235558190.html

    "The next project, we are working on for Teva has a high public profile. As many of you know, Mylan's EpiPen product has been the subject of considerable public discussion over the past year and we will continue to work closely with Teva to help bring their generic version to the market. Teva has submitted all answers to all the questions in the complete response letter and is engaged in an ongoing dialog with the FDA.
    We continue to believe that there is a potential for a late 2017 or early 2018 launch of an AB rated generic and have indicated that a successful conclusion of this project remains a high priority for them. We continue to build and ship pre-launch quantities of Epi devices to Teva and are nearing the completion of the pre-launch quantity purchase order"

    GO ATRS!!!

    Edited Transcript of ATRS earnings conference call or presentation 9-May-17 12:30pm GMT
    Q1 2017 Antares Pharma Inc Earnings Call
  • how long does this bleeding last ....
  • I think Nam...errr...Dennis, forgot what happened last time ATRS (then AIS) was added to the Russell in 2010....
    OK Nam, time to do some homework...